HR+/HER2- Early Breast Cancer Clinical Trials in Hangzhou, Zhejiang
2 recruitingHangzhou, Zhejiang, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07616453
Recruiting
Phase 2
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled3 locationsNCT07616427